A potential COVID-19 vaccine developed by AstraZeneca Plc and Oxford University produced a strong immune response in older adults, giving hope it may protect some of those most vulnerable to the disease, data from mid-stage trials showed. "Our hats off to Dr Onyema Ogbuagu at Yale who helped develop a COVID-19 vaccine".
Tedros said the significance of this scientific achievement can not be overstated, reports UNB citing UN News.
This would mean Sputnik V is "cheaper than mRNA vaccines with similar efficacy levels", the institute said, referring to the Pfizer/BioNTech and Moderna candidates.
The German government has launched a special program for the development of a COVID-19 vaccine for 750 million euros (892.5 million USA dollars), funding the German companies BioNTech, CureVac and IDT Biologika.
"This invaluable collaboration will go a long way to ensure that enough transport capacity is in place for this historic and mammoth operation", Director of UNICEF's Supply Division Etleva Kadilli said in a statement.
Tedros Adhanom Ghebreyesus was speaking at a virtual briefing in Geneva.
He said that currently 50 diagnostics are under evaluation; rapid antigen diagnostics are now available for low- and middle-income countries; while life-saving treatments are being rolled out and new medicines tested.
Despite the excellent progress, Tedros said that "only a fundamental change in funding and approach will realize the full promise of the ACT Accelerator".
"This could be the beginning of the end of the pandemic", he said.
"The International Monetary Fund estimates that if medical solutions can be made available faster and more widely, it could lead to a cumulative increase in global income of nearly United States $9 trillion by the end of 2025", he said.